Regeneron Takes Action Against Ebola with Inmazeb Donation
Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) is recognized as a groundbreaking treatment approved by the U.S. Food and Drug Administration (FDA) for the Ebola infection caused by Orthoebolavirus zairense, commonly known as Zaire ebolavirus.
Currently, supply efforts are accelerating to help address the ongoing outbreak in the Democratic Republic of Congo (DRC).
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has announced the decision to donate up to 500 doses of Inmazeb to the World Health Organization (WHO). This donation is specifically aimed at governments in low- and lower-middle-income countries, ensuring that this crucial life-saving treatment remains accessible and free, especially where the risk of Ebola outbreaks is highest.
"Ebola poses a significant threat due to its high contagiousness and fatality rates, reaching up to 90% if left untreated," remarks Leonard S. Schleifer, M.D., Ph.D., who is the Board co-Chair, President, and Chief Executive Officer of Regeneron. He emphasizes the responsibility to alleviate barriers that could hinder patient access to this vital medicine.
Regeneron’s commitment to combating Ebola was evident during the 2018 outbreak when the company pioneered the development of Inmazeb, using their unique VelociSuite technology, which redefined the landscape of treatments available for Ebola.
Inmazeb's Role in Current Threats
In tandem with the WHO’s agreements, Regeneron is facilitating the swift delivery of Inmazeb to assist in the current outbreak in the DRC. The organization has been collaborating with various public health agencies and non-governmental organizations since 2018, providing the treatment free of charge to any nation facing an outbreak.
To date, Inmazeb has been administered to 266 patients under a compassionate use protocol, reflecting Regeneron's dedication to public health.
Understanding Inmazeb
Inmazeb is FDA-approved for treating infections caused by Orthoebolavirus zairense in both adult and pediatric populations, including newborns born to mothers who are positive for this virus. This treatment showcases Regeneron's advanced VelocImmune platform, combining three specific monoclonal antibodies to neutralize the virus effectively. By hindering the virus's ability to infect cells or rallying the immune system to target infected cells, Inmazeb stands as a significant advancement in antiviral treatment.
Clinical Success and Emerging Guidelines
The efficacy and safety of Inmazeb were notably validated through the PALM Trial, which included 681 participants during the 2018 DRC outbreak. This trial garnered attention upon its early discontinuation after establishing Inmazeb's clear superiority in reducing mortality compared to other treatments.
Since its FDA approval in 2020, Inmazeb has been highly regarded, culminating in the WHO’s inclusion of the treatment as a recommended option in 2022. Remarkably, this treatment was then added to the WHO Essential Medicines List in 2023, marking it as the inaugural Ebola treatment to achieve this status of prequalification for quality and safety.
Regeneron's Commitment to Public Health
With existing stockpiles for Inmazeb not only in the U.S. but also in various low- and middle-income nations, Regeneron's global outreach reflects their commitment to making life-saving medicines available. They have also collaborated with various governments to establish these essential stockpiles, promoting better health outcomes worldwide.
Contacting Regeneron
Media Relations
Alexandra Bowie
Phone: +1 (914) 847-3407
Email: Alexandra.Bowie@regeneron.com
Investor Relations
Mark Hudson
Phone: +1 (914) 847-3482
Email: mark.hudson@regeneron.com
Frequently Asked Questions
What is Inmazeb?
Inmazeb is an FDA-approved treatment specifically designed for infections caused by the Zaire ebolavirus, focusing on both adults and children.
How can Regeneron’s donation help countries?
The donation of Inmazeb enables vulnerable populations in low-income countries to access this treatment free of charge during Ebola outbreaks.
What are Monoclonal Antibodies?
Monoclonal antibodies are lab-made molecules engineered to serve as substitute antibodies that can restore or enhance the immune system's attack on viruses like Ebola.
Why is access to Inmazeb crucial?
Access to Inmazeb is critical as it can significantly enhance survival rates for Ebola-infected individuals, particularly in regions frequently affected by the virus.
How does Regeneron ensure distribution of Inmazeb?
Regeneron collaborates with global health organizations and governments to establish efficient supply chains and stockpiles to facilitate quick distribution during outbreaks.
